

Assessing the risk of COVID-19 epidemic resurgence

in relation to the Delta variant and to vaccination passes

Tyll Krueger^{1,†}, Krzysztof Gogolewski^{2,†}, Marcin Bodych^{1,†}, Anna Gambin², Giulia Giordano³, Sarah Cuschieri⁴, Thomas Czypionka^{5,6}, Matjaz Perc^{7,8,9,10}, Elena Petelos^{11,12}, Magdalena Rosińska¹³, and Ewa Szczurek^{2,*}

¹*Faculty of Electronics, Department of Control Systems and Mechatronics, Wrocław University of Science and Technology, Wrocław, Poland*

²*Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland*

³*Department of Industrial Engineering, University of Trento, Trento, Italy*

⁴*Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Msida, Malta*

⁵*Institute for Advanced Studies, Josefstädterstraße 39, 1080, Vienna, Austria*

⁶*London School of Economics and Political Science, Houghton Street, WC2A 2AE, London, UK.*

⁷*Faculty of Natural Sciences and Mathematics, University of Maribor, Koroška cesta 160, 2000 Maribor, Slovenia,* ⁸*Complexity Science Hub*

Vienna, Josefstädterstraße 39, 1080 Vienna, Austria, ⁹*Department of Medical Research, China Medical University Hospital, China Medical*

University, Taichung 404332, Taiwan, ¹⁰*Alma Mater Europaea, Slovenska ulica 17, 2000 Maribor, Slovenia*

¹¹*Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Heraklion, Greece,* ¹²*Department of Health Services*

Research, CAPHRI-Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands

¹³*Department of Infectious Disease Epidemiology and Surveillance, National Institute of Public Health, Warsaw, Poland.*

[†]*Shared first authorship, * Correspondence: szczurek@mimuw.edu.pl*

Abstract

The introduction of COVID-19 vaccination passes (VPs) by many countries coincides with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.** wide-spread immunity surveillance, and/or minimal long-term common restrictions.

30 Introduction

31 In the past, governments have required proof of vaccination for travel, with yellow fever being the best-
32 known example, and the only disease for which a certificate is needed as a precondition of entry to a
33 country in compliance to the International Health Regulations [1]. However, the idea that proof of vac-
34 cination will become a prerequisite for crossing borders or to enter facilities, visit businesses premises,
35 participate in events, and generally enjoy more freedom, has only arisen in the context of combatting
36 the COVID-19 epidemic. Despite technical challenges, scientific uncertainties, and ethical and legal
37 dilemmas, the idea of VPs, i.e., documents issued on the basis of vaccination status, is now receiving
38 unprecedented attention [2, 3, 4]. The Commission of the European Union (EU), in an effort to ensure a
39 uniform pan-European approach, as similar initiatives for VPs were emerging at national level, put forth
40 a proposal for a framework of issuing, verifying and accepting interoperable vaccination certificates to
41 be implemented across the EU [4], along with a corresponding proposal for third-country nationals re-
42 siding in the EU [5]. The proposal, in its amended form, for the ‘Digital COVID Certificates’ (DCCs),
43 took effect on July 1, 2021. Many consider the EU DCCs, and other forms of VPs in general, as tools to
44 restore people’s freedoms and increase well-being, whilst allowing economies to reopen. Finally, even
45 without VPs, vaccinations alone may result in less stringent behavior. Those vaccinated may feel more
46 secure and restrict themselves less from contacts they would refrain from when not being vaccinated.

47 The introduction of VPs and consequent changes in behavior coincided with the emergence of new
48 variants of concern of the virus [6]. Notably, the Delta variant (B.1.617.2) was detected in many countries
49 across Europe, causing a resurgence of COVID-19 in the United Kingdom at a startling pace [7, 8]. Delta
50 has been estimated to be 50% more transmissible than the Alpha variant (B.1.1.7), already estimated to
51 be 50% more transmissible than the parental strain [9, 10, 11].

52 Evidence indicates vaccine effectiveness can greatly vary [12, 13] and it may be compromised due
53 to escape variants [14] and waning immunity [15, 16, 17, 18]. Preliminary data from several countries
54 indicate reduced vaccine effectiveness against the infection with the Delta variant compared to the Alpha
55 variant [19, 20, 21], even as low as 64% for the Comirnaty (Pfizer-BioNTech) vaccine according to
56 unpublished data from Israel [22]. Emerging evidence suggests that the vaccines are still highly effect at
57 preventing serious illness and hospitalization [11, 20, 21].

58 Still, avoiding another COVID-19 infection resurgence remains a valid and potentially attainable
59 goal [23]. An estimated 10% of COVID-19 infections will have long-term sequelae (long COVID),
60 posing an increasing threat to national health systems [24, 25]. Finally, large numbers of infected create

61 a large pool of virus hosts, resulting in more replications of the virus and higher chances of emergence
62 of mutations conferring evolutionary advantage, including increased transmissibility and antigenicity.
63 To detect the emerging variants, wide-spread surveillance of genetic and antigenic changes in the virus
64 population has to be conducted, together with experiments elucidating their phenotypic implications [26].
65 Such needed comprehensive surveillance and experiments may become stalled for a large population
66 of infected. Given these circumstances, it is critically important to understand the impact of key risk
67 factors such as: vaccine ineffectiveness, slow vaccination rate, waning immunity, fraction of individuals
68 in the population who will never become vaccinated, and finally the levels of restrictions, on infection
69 dynamics. Not being aware of the risks and their consequences, and a false sense of security, including
70 when approaching higher vaccination coverage, may result in policymakers opting to select suboptimal
71 levels of restrictions.

72 Various models have been developed to inform vaccination strategies [27, 28, 29, 30, 31, 32, 33,
73 34, 35]. One such effort indicates lower vaccine effectiveness coupled with an increase in social contact
74 among those vaccinated (behavioral compensation) may undermine vaccination effects, even without
75 considering immunity waning [36, 37]. Scenarios for the post-vaccination era were also considered by
76 Sandmann and colleagues (2021), finding that under realistic scenarios periodic epidemics are likely [38].
77 So far, there has been no model to focus on the medium- and long-term impact of relaxing restrictions
78 for VP holders, with due consideration to vaccine effectiveness, durability of response, and vaccine
79 hesitancy, especially in the context of the increased transmissibility of the Delta variant. Given the
80 implementation of the EU DCC, and emerging heterogeneous measures on utilising the VPs for different
81 purposes at national level by establishing different levels of freedom for VP holders in terms of accessing
82 premises, facilities, travelling within a country, etc., it is important to examine the broad parameters
83 determining how to optimise the implementation of measures such as the EU DCC and other VPs.

84 To address these needs, we propose a mathematical VAP-SIRS model, which accounts for key pa-
85 rameters affecting current infection dynamics, such as for lower restrictions for VPs holders than for the
86 rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and
87 waning immunity, and the increased transmissibility of the Delta variant, which all impact the effective
88 reproduction number of the virus. The model predicts the impact of restrictions for VP holders and the
89 rest of the population on epidemic thresholds for various parameter settings, and delivers a systematic
90 framework to assess key considerations for policymaking.




Figure 1: The VAP-SIRS model and its predicted scenarios. **a**. Graphical scheme of the VAP-SIRS model. **b, c**. Predicted scenarios for the reference setup for the Delta variant, with vaccine effectiveness $a = 0.79$ (corresponding to the effectiveness of the Comirnaty vaccine against infection with the Delta variant), slow (re-)vaccination rate ($v = v_r = 0.004$; typical for many European countries), slow immunity waning $\omega = 0.002$, low fraction of never-vaccinated ($d = 0.12$; corresponding to the fraction in the United Kingdom) and proportional mixing (see Methods). **b**. Color curves: Timeline of daily incidence per 1 million inhabitants in different infected compartments for the combination of restrictions $f = 0.77$ and $f_v = 0.55$. A variable with the asterisk (*) indicates that we consider a daily incidence over the corresponding variable, and by I_Σ^* we mean the sum of all daily infected ($I_D^* + I_N^* + I_1^* + I_2^*$). Color bands: Muller plot of the population structure (the width of the color band in the y axis) as a function of time (x axis) for the same parameter settings; by I_Σ and R_Σ we denote $I + I_V$ and $R + R_V$, respectively. **c**. Time evolution of the instantaneous reproduction number R^* (y axis) depending on the number of days counted from the start of the vaccination program (x axis), in five different scenarios describing the epidemic evolution: overcritical (+, red, $f = 0.77$ and $f_v = 0.38$), subcritical (-, blue, $f = 0.92$ and $f_v = 0.71$), initially and eventually overcritical (+++, orange, the same restrictions as in **b**: $f = 0.77$ and $f_v = 0.55$), eventually overcritical (-+, pink, $f = 0.92$ and $f_v = 0.38$), and eventually subcritical (+-, cyan, with $f = 0.77$ and $f_v = 0.71$). As controls, two additional scenarios of the epidemic evolution are presented, corresponding to no implementation of VPs and no changes in behavior due to vaccination: subcritical (another example of - scenario, green) with $f = f_v = 0.92$ and eventually subcritical (another example of +- scenario, yellow) with $f = f_v = 0.77$, both plotted with dot-dashed line.

91 Results

92 The VAP-SIRS model of the impact of COVID-19 VPs

93 The VAP-SIRS model extends the classical SIRS model [39] (red arrows in Figure 1a) with additional
 94 states and parameters that describe the dynamics of vaccination rollout in a population (green arrows in
 95 Figure 1a). To this end, we consider the following subpopulations: (i) initially susceptible S_N , who, if
 96 successfully vaccinated, populate the immune group V , with rate av , where v is the vaccination rate

97 and a is the vaccination effectiveness, (ii) susceptible who were vaccinated but did not gain immunity
98 (S_1), (iii) vaccinated, whose immunity waned with rate ω and who became susceptible again (S_2), (iv)
99 susceptible, who are not and will never get vaccinated (S_D). The S_D compartment contains people
100 who for health reasons cannot receive current types of vaccines, as well as individuals who do not get
101 vaccinated because of hesitancy, beliefs or other individual reasons. The fraction of the population that
102 will never be vaccinated is denoted by d . Additionally, revaccination of S_2 populates V with rate av_r .
103 All recovered, unless in the recovered compartment R_D , are also subject to vaccination. Before the
104 recovered in the R_V lose immunity, they might be revaccinated, and, thus, populate the V group with
105 rate v_r (similarly, R_N are vaccinated with rate v). In this case, vaccination effectiveness is fixed to
106 1, which is substantiated on the basis of the fact that vaccination combined with a previous infection
107 should confer a much stronger protection than only vaccination of a susceptible individual. Across the
108 manuscript, we assume the revaccination and vaccination rates are equal, $v_r = v$.

109 The presented model analysis is performed for carefully selected parameter setups. We consider
110 two different vaccination rates a , 0.004 and 0.008 doses per person daily, chosen on the basis of the
111 current rates observed in Europe [40, 41]. As vaccine effectivenesses for the Delta variant, we consider
112 0.6 and 0.79, which were reported as the effectivenesses of the most widely used vaccines: Vaxzevria
113 (AstraZeneca) and Comirnaty (BioNTech/Pfizer) respectively for this variant [20]. For the Alpha
114 variant, the effectivenesses of the same vaccines for that variant are considered instead, namely 0.79
115 (Vaxzevria) and 0.92 (Cominarty) [20]. We consider realistic fractions d of never-vaccinated equal
116 to 0.12 (optimistic), and 0.3 (pessimistic), reported for the United Kingdom and France, respectively
117 [<https://ourworldindata.org/>, as of June 15th, 2021]. Furthermore, two post-vaccination immunity wan-
118 ing rates ω are considered corresponding to optimistic (500 days; $\omega = 1/500$) and pessimistic (200 days;
119 $\omega = 1/200$) average immunity duration periods, reflecting emerging data on large individual variation
120 of immunity waning and other key factors influencing this process [15, 18, 42, 43, 44]. There remains
121 uncertainty regarding the waning time for natural immunity, and whether it varies between the different
122 SARS-CoV-2 variants, but early evidence indicates it lasts at least 180 days [45, 46, 47]. Hence, we
123 consider an optimistic scenario of natural immunity lasting on average similarly long as the optimistic
124 immunity gained via vaccination: 500 days (corresponding to natural immunity waning rate $\kappa = 0.002$).
125 Based on the current studies, we fix the generation time to 6 days ($\gamma = 1/6$) [48, 49].

126 We assume that VP holders are all those who completed at least one complete vaccination cycle, i.e.,
127 one dose or two doses depending on the vaccine used (Fig. 1), which is also the basis on which the EU
128 DCC is issued. The restriction level (ranging from 0 to 1) is introduced as a modulator of the SARS-

129 CoV-2 reproduction number. Here, we consider that without any restrictions, the basic reproduction
130 number for the B.1.617.2 variant (Delta) is equal to 6 (an optimistic estimate based on [50, 51]), while
131 for the B.1.1.7 variant (Alpha) an optimistic estimate is equal to 4 [48, 49]. Two levels of restrictions are
132 considered: restrictions f_v for contacts among VP holders, as well as restrictions f for contacts of the VP
133 holders with the rest of the population and for contacts within the rest of the population. The impact of
134 VPs is studied assuming that $f_v < f$: a VP holder has more freedom of contact with other VP holders, or
135 is generally subject to fewer restrictions on the VP holders than the rest of the population. Importantly,
136 in general f and f_v should be interpreted as the net effect of all combined factors that reduce the repro-
137 duction number of the virus within the respective groups: all applied non-pharmaceutical interventions,
138 including testing and isolation, together with the resulting changes in behavior. The situation where no
139 VPs are implemented, hence the vaccinated have the same restrictions as the rest of the population, and
140 there are no changes of behavior due to vaccination, is modeled by fixing $f_v = f$. Finally, to analyze
141 the impact of social behavior, we consider two types of mixing between subpopulations: proportional
142 (typical for SIR models) and preferential, where the VP holders prefer contacts with other VP holders.
143 See Methods for a detailed model description.

144 **VAP-SIRS predicts a possible infection resurgence despite vaccinations**

145 VAP-SIRS predicts unfavourable epidemic dynamics for a wide range of parameters, both for the Delta
146 and the Alpha variants. As an example consider the Delta variant, and vaccine effectiveness $a = 0.79$ (the
147 effectiveness of the Comirnaty vaccine against the Delta variant), (re-)vaccination rates $v = v_r = 0.004$,
148 low never-vaccinated fraction $d = 0.12$ (reported for the United Kingdom), low immunity waning rate
149 $\omega = 0.002$, low natural immunity rate loss $\kappa = 0.002$, and proportional mixing. This set of parameters
150 corresponds to a seemingly safe setup, which we will call the reference setup. The impact of various
151 parameter changes with respect to this reference will be considered below. For such a setup, consider
152 medium-high restrictions level $f = 0.77$ for contacts of the VP holders with the rest of the population
153 and within the rest of the population, along with a restrictions reduction for the VP holders compared to
154 the rest of the population by around 30%, resulting in medium restrictions $f_v = 0.55$ for VP holders.
155 For these parameters, the model predicts a small wave of infections shortly after the vaccination program
156 starts, followed by a large wave later (color curves Fig. 1b). This behavior is explained by the population
157 structure (Muller plot, Fig. 1b) and can only happen due to the different levels of restrictions for the
158 VP holders and the rest of the population. In this scenario, the first wave is driven by the unvaccinated
159 susceptibles (S_N) and suppressed by ongoing vaccination, as expected. Interestingly, the second, larger

160 wave is driven by the S_V group. The S_V group is composed of the number of individuals for whom the
161 vaccine was ineffective (S_1) and those vaccinated who lose their immunity and are not yet revaccinated
162 (S_2).

163 **Stability analysis identifies potential scenarios for the COVID-19 epidemic depending on** 164 **the restrictions imposed on VP holders and the rest of the population.**

165 To assess the epidemic evolution in different scenarios, we analyse stability by linearising the model
166 equations with $I = R = 0$ and introduce the *instantaneous reproduction number* R^* (see Methods).
167 $R^*(t)$ is the reproduction number that would be observed at time t , given the restrictions $\mathbf{f} = (f, f_v)$
168 and the composition of the population, where the number of infected is very small. For $R^*(t) > 1$,
169 switching to \mathbf{f} at time t results in an *overcritical* epidemic evolution, with an initially exponential growth
170 of infections; for $R^*(t) < 1$, switching to \mathbf{f} at time t results in a *subcritical* epidemic evolution, where
171 the number of active cases decreases to zero. The R^* is more informative of epidemic thresholds than
172 the standard effective reproduction number, as it does not depend on the actual number of infected and
173 recovered.

174 Assuming the reference setup for the Delta variant, we consider five choices of restriction combina-
175 tions (prototypical for five regions of the parameter space, see Figure 2), leading to different time profiles
176 of R^* (Fig. 1c). As control setups, we introduce two settings that represent policies in a given population
177 without the implementation of the VPs, one with a common high restriction level $f = f_v = 0.92$, which
178 keeps the epidemic subcritical (scenario denoted $-$, green dot-dashed line in Fig. 1c), and one with a
179 common medium-high restriction level $f = f_v = 0.77$, which results in a time evolution fo R^* from
180 overcritical to subcritical (denoted $+ -$, yellow dot-dashed line in Fig. 1c). In such settings, in case VPs
181 are introduced, VP holders can gain low ($< 20\%$), medium (20-50%) or high ($> 50\%$) restriction reduction
182 with respect to the restrictions for the rest of the population. Granting high restriction reductions to VP
183 holders, both with mid-high and with high restrictions enforced for the rest of the population, eventually
184 leads to an overcritical epidemic (red and pink curve in Fig. 1c: the red curve shows a persistent overcrit-
185 ical epidemic, a scenario denoted $-$, while the pink curve shows an epidemic that is initially subcritical
186 and then becomes overcritical, a scenario denoted $- +$). Medium restriction reductions for VP holders,
187 along with high restrictions for the rest of the population, yield a subcritical epidemic evolution (another
188 example of scenario $-$, blue curve in Fig. 1c). When mid-high restrictions are enforced for the rest of the
189 population, a medium restriction reduction for VP holders leads to an epidemic that is initially overcriti-
190 cal, then becomes subcritical and after a few months switches to overcritical again, starting a new wave

191 of infections (orange curve in Fig. 1c; denoted $++$, this is also the scenario shown in the simulation
192 in Fig 1b). Finally, always with mid-high restrictions enforced for the rest of the population, a low
193 restriction reduction for VP holders leads to an epidemic that is initially overcritical and then switches to
194 subcritical (another example of scenario $+ -$, cyan curve in Fig 1c).

195 In each scenario we computed the time evolution of the *instantaneous doubling time* D , capturing
196 how fast the infections grow. For a given \mathbf{f} , $D(t)$ is the doubling time that would be observed for the
197 growth of a small initial number of infections at time t , with enforced restrictions \mathbf{f} . Very short doubling
198 times, below 30 days, can be observed in three scenarios that are (eventually) overcritical: see the red,
199 orange and pink curves in the Supplementary Fig. S1.

200 **Flexible measures are required to avoid epidemic resurgence depending on parameter** 201 **setups**

202 The relevant $f - f_v$ parameter space, where $f_v \leq f$, can be divided into five regions, where the epidemic
203 dynamics follows the distinct patterns exemplified in Fig. 1c. Fig. 2 shows the impact of changing
204 specific single parameter values on the expected scenarios and on times to critical events, tracking time
205 up to two years. The area occupied by each region changes depending on the parameter setups. For
206 example, in the reference setup for the Delta variant ($a = 0.79$ - the Comirnaty effectiveness on the
207 Delta variant, $v = v_r = 0.004$, $d = 0.12$ - the fraction of never vaccinated in the United Kingdom,
208 $\omega = 1/500$, $\kappa = 1/500$, and proportional mixing) in Fig. 2a, the overcritical region (denoted $+$, with
209 R^* always above 1) occupies the lower left corner. This region is enlarged in the case of a lower vaccine
210 effectiveness ($a = 0.6$ - the effectiveness of Vaxzevira on the Delta variant, Fig. 2b), and higher waning
211 rate (Fig. 2f). In contrast, it shrinks with a higher vaccination rate (Fig. 2c), indicating that there is
212 a concrete benefit from deploying efficient vaccination programs. The subcritical region ($-$, with R^*
213 always smaller than 1) lies in the opposite corner of the $f - f_v$ space, for larger restriction values, and,
214 for a fixed fraction of never-vaccinated d , tends to decrease for setups where the overcritical region
215 increases. As expected, the switch to a larger fraction of never-vaccinated (to $d = 30\%$, corresponding
216 to the reported fraction in France), increases the overcritical ($+$) region (Fig. 2e). But, at the same time,
217 the larger fraction of never-vaccinated increases also the subcritical ($-$) region. This is due to the fact that
218 the never-vaccinated are assumed to follow stricter restrictions, compared to VP holders, and therefore
219 their larger fraction can constrain the emergence of the later waves, characteristic of the regions $++$ and
220 $-+$. Still, a strategy relying on this effect might be difficult to implement due to the large $+$ region and
221 can lead to undesirable outcomes in practice.




Figure 2: Possible COVID-19 epidemic dynamics for different parameter setups for the Delta variant. The relevant $f - f_v$ parameter space, where $f_v \leq f$, can be divided into five regions (delimited by black borders), each associated with a different behavior of the epidemics. On the diagonal (white dashed line), $f = f_v$, i.e., the restrictions for VP holders and for the rest of the population are the same - corresponding to the situation when VPs are not introduced at all. Lower triangles show the time until the last critical threshold: different colour scales correspond to the time until the switch either from a subcritical to an overcritical epidemic (time until overcriticality, violet-green scale), or from an overcritical to a subcritical epidemic (time until subcriticality, yellow-pink scale). Upper triangles show the asymptotic R^* , as a function of the values of f and f_v (blue-red scale, with blue associated with $R^* < 1$ and red associated with $R^* > 1$). **a.** Reference setup, with $a = 0.79$ (corresponding to the effectiveness of the Comirnaty vaccine on the Delta variant), $v = v_r = 0.004$, $\omega = 0.002$, $d = 0.12$ (fraction of never-vaccinated in the United Kingdom) and proportional mixing. The choices of (f, f_v) corresponding to the five scenarios exemplified in Fig. 1c are denoted by points of the same colour. **b.** Setup with a decreased vaccine effectiveness: $a = 0.6$ (corresponding to the effectiveness of the Vaxzevria vaccine on the Delta variant). **c.** Setup with an increased vaccination rate: $v = v_r = 0.008$. **d.** Setup with preferential (instead of proportional) mixing **e.** Setup with an increased fraction of people who will not get vaccinated: $d = 0.3$ (fraction of never-vaccinated in France). **f.** Setup with an increased waning rate: $\omega = 1/200$.

222 Inside each of the three regions associated with the $++$, $-+$, $+-$ scenarios in Fig. 1c, the specific
 223 parameter settings differ by the time to the critical threshold of interest for that region (the last ob-
 224 served switch between subcritical and overcritical epidemic, which for the $++$ region, for example, is
 225 the second critical threshold; see Methods for the computation of the times to critical thresholds). For

226 the reference setup (Fig. 2a) and the $+ - +$ region, the critical threshold is reached after a minimum ~ 4
227 months. Decreasing the vaccine effectiveness from Comirnaty's to Vaxzevira's (Fig. 2b), as well as in-
228 creasing the waning rate (Fig. 2f), leads to overcriticality sooner, after a minimum of ~ 2 and ~ 3 months
229 respectively, for low f_v values. Increasing vaccination rate (Fig. 2c) shrinks the $+ - +$ region. The com-
230 parison between proportional and preferential mixing shows the impact of more intense interactions of
231 the VP holders inside of their own group, and less intense contacts of the VP holders with the rest of
232 the population. With preferential mixing (Fig. 2d), the $+ - +$ region becomes larger and overcriticality is
233 reached even sooner. This is due to the fact that preferential contacts among VP holders accelerate the
234 emergence of the wave caused by infections of the VP holders. Seemingly counter-intuitively, increasing
235 the number of never-vaccinated people (Fig. 2e) shrinks the $+ - +$ region and delays the onset of overcrit-
236 icality. This is due to the fact that the onset of overcriticality in the $+ - +$ region depends not only on the
237 intensity of contacts of the VP holders, but also on their fraction in the population; with a larger fraction
238 of never-vaccinated, the fraction of VP holders in the population decreases.

239 The above analysis of the different regions predicts a possible switch to overcritical epidemic growth
240 for a given parameter setup and, if there is a switch, it provides the time it happens, counting from the
241 onset of the vaccination program. It does not, however, indicate how fast the overcritical growth will be.
242 To inform about what growth rates can be eventually expected in the overcritical regime, we compute
243 the asymptotic R^* (the $R^*(t)$ for $t \rightarrow \infty$, see Methods) for all parameter setups and all combinations
244 of restrictions in the relevant $f - f_v$ space. For a given restriction combination \mathbf{f} , the asymptotic R^*
245 indicates how quickly the infections grow shortly after the restrictions are set to \mathbf{f} in the asymptotic state.
246 For all considered parameter setups, except for the one with high (re-)vaccination rate, and for all except
247 the $+ -$ and the $-$ regions, large asymptotic R^* can be expected, which corresponds to short doubling
248 times (Fig. 2). This analysis highlights the importance of avoiding the overcritical (+) region, as there
249 the asymptotic R^* values can even exceed 2 when the restrictions are low.

250 Comparing Figure 2 to Supplementary Figure S2 shows how the Delta variant worsens all scenarios
251 with respect to the Alpha variant: in all panels of Figure 2, the Delta variant leads to a considerable
252 expansion of the overcritical region, shrinking of the safe subcritical region, and to consistently larger
253 values of asymptotic R^* . This is due not only to a higher transmissibility of the Delta variant, but also
254 due to the fact that the considered vaccines have lower effectiveness for this variant, as compared to the
255 Alpha variant.

256 We further investigate how the expected scenarios, times to critical events (tracking time up to two
257 years), and asymptotic R^* values are affected by changes of two parameters at once, compared to the




Figure 3: Possible COVID-19 epidemic dynamics for parameter setups with two changes w.r.t. the reference setup, for the Delta variant (changes as in Table 1, rows 6-11) Colors of the lower triangles correspond to the time until critical changes in epidemic dynamics, while the colors of the upper triangles correspond to the values of asymptotic R^* , as in Fig. 2 a. Setup with decreased effectiveness $a = 0.60$ (corresponding to the effectiveness of the Vaxzevira vaccine on the Delta variant), and increased (re-)vaccination rates $\nu = \nu_r = 0.008$. **b.** Setup with decreased $a = 0.60$ and increased fraction of never vaccinated $d = 0.30$ (corresponding to the change from the fraction of never-vaccinated in the United Kingdom to the fraction of never-vaccinated in France). **c.** Setup with decreased $a = 0.60$ and increased waning rate $\omega = 0.005$. **d.** Setup with increased $\nu = \nu_r = 0.008$ and increased $d = 0.30$. **e.** Setup with increased $\nu = \nu_r = 0.008$ and increased $\omega = 0.005$. **f.** Setup with increased $d = 0.30$ and increased $\omega = 0.005$.

258 reference setup, for the Delta (Fig. 3) and the Alpha variant (Supplementary Fig. S3). The double pa-
 259 rameter changes give insight into the possible synergistic and compensatory effects between individual
 260 parameter changes. Compared to the effect of only decreasing the vaccine effectiveness from Comir-
 261 naty's to Vaxzevira's (Fig. 2b), the effect of jointly decreasing the vaccine effectiveness and increasing
 262 the vaccination rate (Fig. 3a) indicates that a higher vaccination rate can compensate to some extent for
 263 the loss of effectiveness. Similarly, an increased vaccination rate can counteract increased immunity
 264 waning rate (Fig. 3e). The combination of decreased effectiveness and increased immunity waning rate
 265 has the worst effect, as it largely increases the overcritical region (+), decreases the subcritical region

266 (–) and accelerates the times to the overcriticality in all other regions (Fig. 3c). Finally, combinations of
267 an increased never-vaccinated fraction with other parameter changes show an interesting mix of effects.
268 When both the never-vaccinated fraction and the vaccination rate increase, the overcritical (+) region
269 decreases and the subcritical region increases, while the times to overcriticality in the $++$ and the $-+$
270 regions increase (Fig. 3d). Similarly, there is a synergistic effect of the combination of the increased
271 never-vaccinated fraction and the increased immunity waning rate (Fig. 3f). For the Alpha variant, the
272 effects of coupled parameter changes combine the same way as for the Delta variant, but once again it is
273 apparent that, for all the parameter setups we considered, with the Alpha variant much less restrictions
274 are required to avoid epidemic resurgence than with the Delta variant (Supplementary Fig. S3).

275 Taken together, these results indicate that, unless novel vaccines with higher effectiveness are in-
276 vented and distributed, and unless much faster and wider vaccination programs are implemented, re-
277 sulting in much more favorable parameter settings than the realistic ones analysed here (including those
278 considered optimistic), highly unfavorable infection dynamics are likely to emerge for the Delta variant,
279 and less, but still, for the Alpha variant. The $-+$ and $++$ regions in Figures 2 and 3 can seem attractive as
280 restriction policies, because they entail larger freedom for the VP holders; both these regions, however,
281 eventually result in epidemic resurgence and either should be avoided or the time spent in these regions
282 should be very carefully regulated. For example, if sufficient restrictions are enforced for the rest of the
283 population, the VP holders may initially be granted additional freedoms (larger if the Alpha variant is
284 dominant in the population, and much lower if the Delta variant is dominant), which corresponds to the
285 $-+$ region. In this way, an overcritical situation (region +) will be avoided. However, to prevent the
286 epidemic from becoming overcritical after an initial decline in case numbers, restrictions on VP holders
287 need to be timely increased and adapted, to avoid spending longer time in the $-+$ region than the time
288 to overcriticality. Thus, moving out of the $-+$ region to the $+-$ region with the right timing could be
289 one of possible strategies. It may, however, be more practical to circumvent many changes of restriction
290 policies over time and it may be fair for everyone to face the same restrictions. Safe common restrictions,
291 however, corresponding to the parameters on the diagonal in the subcritical (–) region or Figures 2 and
292 Fig. 3 and Supplementary Figures S2 and Fig. S3, are relatively high, especially those required by the
293 Delta variant, and may therefore cause unrest in the population.

294 **A minimum common restriction level can keep the epidemic subcritical in the long-term**

295 We compute the minimum common restriction level f_{\min} for the whole population that would guarantee
296 to avoid an overcritical epidemic in the long-term (for time approaching infinity, Methods):

$$f_{\min} = \max(0, 1 - 1/(R_{\max} \cdot (1 - V^{\text{as}})),$$

297 where V^{as} as is the asymptotic fraction of the immunized in the population

$$V^{\text{as}} = (1 - d) \frac{a}{1 + \omega/v_r}.$$

298 The resulting values differ depending on the setups of vaccine effectiveness a , revaccination rate v_r ,
299 the fraction of never-vaccinated population d and immunity waning rate ω (Tab. 1). The minimum
300 common restrictions for the reference setup are equal to $f_{\min} = 0.69$. Out of parameter setups with
301 single change compared to the reference, doubled (re-)vaccination speed leads to the lowest possible
302 common restriction level. Even for this most optimistic setup (high $a = 0.79$, high $v_r = 0.008$, low
303 $d = 0.12$, low $\omega = 0.002$; Tab. 1 third row) we obtain $V^{\text{as}} = 0.6$, and $f_{\min} = 0.62$. The level of
304 0.62 restrictions is around twice as high as the level 0.29 that would be required for the Alpha variant
305 (Supplementary Tab. 1), and is a considerable reduction of freedom compared to before the pandemic. It
306 is noteworthy that in the long term, to avoid infections rising, minimum common restrictions have to be
307 increased to 0.74 with the larger fraction of never vaccinated d . Thus, a scenario with a large fraction of
308 the population without immunity gained via vaccination requires long-term high restriction levels, and
309 as such seems politically unfeasible.

310 When changing two parameters simultaneously in order to assess synergies, we find that a decreased
311 vaccine effectiveness or an increased share of never vaccinated or an increased waning rate can barely
312 be offset by an increase in vaccination speed. Both a decreased vaccine effectiveness and an increase
313 in the share of never vaccinated in combination with an increased waning rate considerably increase the
314 minimum restriction level that is adequate to ensure resurgence can be avoided. The latter (increased
315 d , increased ω as compared to the reference) is the most pessimistic of the considered scenarios, with
316 $f_{\min} = 0.8$.

317 This analysis highlights the importance of vaccine effectiveness, vaccination speed, but also of the
318 fraction of the never-vaccinated. Such demanding requirements for stringent minimum common restric-
319 tions could be reduced if novel vaccines with higher effectiveness become available, if faster and wider

	Parameter setup	a	v_r	d	ω	V^{as}	f_{min}
1	Reference setup (ref Fig. 2a)	0.79	0.004	0.12	0.002	0.46	0.69
2	Decreased a (ref Fig. 2b)	0.6	0.004	0.12	0.002	0.35	0.74
3	Increased v_r (ref Fig. 2c)	0.79	0.008	0.12	0.002	0.56	0.62
4	Increased d (ref Fig. 2e)	0.79	0.004	0.3	0.002	0.37	0.74
5	Increased ω (ref Fig. 2f)	0.79	0.004	0.12	0.005	0.31	0.76
6	Decreased a and increased v_r (ref Fig. 3a)	0.6	0.008	0.12	0.002	0.42	0.71
7	Decreased a and increased d (ref Fig. 3b)	0.6	0.004	0.3	0.002	0.28	0.77
8	Decreased a and increased ω (ref Fig. 3c)	0.6	0.004	0.12	0.005	0.23	0.78
9	Increased v_r , increased d (ref Fig. 3d)	0.79	0.008	0.3	0.002	0.44	0.70
10	Increased v_r , increased ω (ref Fig. 3e)	0.79	0.008	0.12	0.005	0.43	0.71
11	Increased d , increased ω (ref Fig., 3f)	0.79	0.004	0.3	0.005	0.18	0.80

Table 1: **Asymptotic level of immunization V^{as} and minimum common restrictions f_{min} for the Delta variant and different parameter setups**, for parameters: vaccine effectiveness a , revaccination rate v_r , fraction of never-vaccinated d , and waning immunity rate ω . The first row concerns the reference setup; rows below are setups with the same parameters as in the reference setup, but with either one parameter changed (in bold; rows 2–5; same as in Figures 2 and 4, apart from preferential mixing, as it is not relevant for common restrictions) or two parameters changed (in bold; rows 6–11).

320 vaccination programs are implemented, and finally, if the never-vaccinated fraction shrinks.

321 **Endemic state analysis reveals the possibility of large daily infection numbers**

322 For a given restriction combination \mathbf{f} , the above analyzed asymptotic instantaneous reproduction number
 323 R^* (Figures 2 and 3, Supplementary Figures S2 and S3) indicates how quickly the infections grow shortly
 324 after the restrictions are set to \mathbf{f} in the asymptotic state; however, it does not provide insight into the
 325 daily infection numbers the system converges to. To this end, we compute the daily infection numbers
 326 both in the vaccinated and the unvaccinated subpopulations in the endemic state, as functions of the
 327 restrictions \mathbf{f} for the Delta variant (Fig. 4) and compare it to the scenarios achieved with the Alpha variant
 328 (Supplementary Fig. S4). In contrast to the computation of the instantaneous reproduction number
 329 R^* and its asymptotic values, which is based on the analysis of the linearized system of the ordinary
 330 equations in the VAP-SIRS model, the endemic state is based on the computation of the stationary point
 331 of the full set of the equations (Methods).

332 For all parameter setups, in all regions apart from the subcritical (–) region, the daily infections in the
 333 endemic state will exceed 10 per million, which is the tolerance threshold for efficient test, trace and iso-
 334 lation policy [52]. For the setups that correspond to low vaccination effectiveness or short waning time,
 335 the endemic state is most unfavorable, as the daily infections can exceed 1000 daily cases per million. A
 336 high (re-)vaccination rate is crucial to expand the safe region (Fig. 4c). A sharp transition can be seen
 337 between favorable and unfavorable parameter setups. In the endemic state, the daily infection numbers

338 in the vaccinated subpopulation can exceed that of the unvaccinated subpopulation, which underlines the
 339 risks of waning immunity.

340 Considering the parameter setups that arise by changing two parameters at once with respect to
 341 the reference setup gives insights about their joint effects, shown in Fig. 5; the effect of simultaneous
 342 parameter variations is akin to that described earlier for the values of asymptotic R^* and time to critical
 343 thresholds in Figure 3.

344 Again, comparison with the endemic infection numbers predicted for the Alpha variant (Supplemen-
 345 tary Fig. S4 and Supplementary Fig. S5) shows that Delta has considerably narrowed opportunities to




Figure 4: Daily COVID-19 infection cases in the endemic state for different parameter setups and the Delta variant. Lower triangles show the daily infection numbers in the unvaccinated, and upper triangles in the vaccinated population in the endemic state of the epidemics, for the relevant $f - f_v$ parameter space, where $f_v \leq f$. Black borders delineate the five regions identified in Figures 2 and 3. Parameter setups as in Figure 2: **a.** Reference setup, with $a = 0.79$ (corresponding to the effectiveness of the Comirnaty vaccine on the Delta variant), $v = v_r = 0.004$, $\omega = 0.002$, $d = 0.12$ (fraction of never-vaccinated in the United Kingdom) and proportional mixing. **b.** Setup with a decreased vaccine effectiveness: $a = 0.6$ (corresponding to the effectiveness of the Vaxzevria vaccine on the Delta variant). **c.** Setup with an increased vaccination rate: $v = v_r = 0.008$. **d.** Setup with preferential (instead of proportional) mixing **e.** Setup with an increased fraction of people who will not get vaccinated: $d = 0.3$ (fraction of never-vaccinated in France). **f.** Setup with an increased waning rate: $\omega = 1/200$.




Figure 5: **Daily COVID-19 infection cases in the endemic state for parameter setups with two changes w.r.t. the reference setup, and the Delta variant.** Lower triangles show the daily infection numbers in the unvaccinated, and upper triangles in the vaccinated population in the endemic state of the epidemics, for the relevant $f - f_v$ parameter space, where $f_v \leq f$. Black borders delineate the five regions identified in Figures 2 and 3. Parameter setups as in Figure 3: **a.** Setup with decreased effectiveness $a = 0.60$ (corresponding to the effectiveness of the Vaxzevira vaccine on the Delta variant), and increased (re-)vaccination rates $v = v_r = 0.008$. **b.** Setup with decreased $a = 0.60$ and increased fraction of never vaccinated $d = 0.30$ (corresponding to the change from the fraction of never-vaccinated in the United Kingdom to the fraction of never-vaccinated in France). **c.** Setup with decreased $a = 0.60$ and increased waning rate $\omega = 0.005$. **d.** Setup with increased $v = v_r = 0.008$ and increased $d = 0.30$. **e.** Setup with increased $v = v_r = 0.008$ and increased $\omega = 0.005$. **f.** Setup with increased $d = 0.30$ and increased $\omega = 0.005$.

346 reduce restrictions for the VP holders, underlining the negative impact of the higher transmissibility of
 347 the Delta variant and lower effectiveness of the vaccines on this variant.

348 Discussion

349 Introducing VPs is widely seen as a means to opening up economies and societies, despite the ongoing
 350 epidemic. A recent complication in this respect is the rise of the Delta variant with its higher trans-
 351 missibility and decreased vaccine efficacy. To inform this discussion, we extend a SIR model to reflect

352 vaccination dynamics and possibly different restrictions for VP holders, with empirical parameters for
353 both the Alpha and Delta variant.

354 VAP-SIRS deliberately keeps several aspects simple. The model is not compartmentalized for age
355 groups and does not explore the impact on hospitalisation or intensive care unit utilization like some other
356 models, albeit in the context of exploring different parameters than larger freedom for VP holders [27,
357 29, 31, 32, 33, 34]. Deaths could be taken into account through a straightforward modification of the
358 model, which would however lead to more parameters. In this case, the fact that vaccination reduces
359 the risk of death would have to be accounted for. The impact of deaths, need for intensive care, or
360 long-COVID cases on public health and society, which is very important especially when the epidemic
361 becomes overcritical, can be indirectly assessed on the basis of the number of cases. In general, features
362 such as age groups do not add further insights into the questions which are the focus of our study,
363 namely, the impact of VPs on infection dynamics and the parameters that increase the risks of overcritical
364 dynamics, given the spread of the Delta variant. In this context, the advantage of our model is that it is
365 enriched in features such as revaccinations and waning immunity, which are particularly relevant in the
366 long term. Avoiding another wave is a prudent goal due to the threats it poses, in the form of long-term
367 health effects, the deleterious impact on societies and the emergence of new variants.

368 Nevertheless, possible extensions to our model could include inter- individual or age-dependent vari-
369 ations in immunity, which would render it relevant for people with severe chronic conditions or im-
370 munodeficiencies. The presented analysis has been performed assuming that without restrictions, the
371 maximum reproduction number of the virus is $R_{\max} = 6$ or $R_{\max} = 4$ for Delta and Alpha variants,
372 respectively. More transmissible variants could easily be modeled by fixing higher values of R_{\max} . Pos-
373 sible future variants, for which existing vaccines may potentially be less effective could be considered
374 using our model by fixing smaller vaccine effectiveness parameter a than the values we considered. We
375 also do not account for seasonality, which seems to have a dampening effect on epidemic dynamics
376 during the summer months, when it is possible to temporarily reduce restrictions. Not all analyzed pa-
377 rameter values are exactly known, such as the post- vaccination or natural immunity waning time. We,
378 however, fix optimistic values for such parameters, and show that unfavorable infection dynamics can
379 still be obtained even under optimistic assumptions.

380 Despite limitations, our model accounts for key parameters influencing infection dynamics and gives
381 valuable insights into policies pertaining to the introduction of VPs, contributing to render the valid goal
382 of avoiding resurgence attainable. We find that a wide range of the VAP-SIRS model parameter choices,
383 even optimistic ones, show the possibility of an epidemic resurgence for both variants. The risk of

384 resurgence is higher in the case of implemented VP, i.e., with VP holders enjoying reduced restrictions,
385 such as being exempt from wearing masks and testing before entering business, gastronomical, or tourist
386 premises. The resurgence can be avoided in the short and in the long run only when the restrictions
387 are kept high for the rest of the population, and the reduction for the VP holders is moderate or small,
388 especially for the Delta variant. The main driver of this phenomenon is the potential lack of immunity
389 of VP holders. With a VP, people enjoy lower restrictions, while some actually remain both susceptible
390 and potentially contagious because the vaccine was ineffective or the immunity has waned.

391 For all analyses, a comparison between values for the Alpha and Delta variants shows that Delta
392 has drastically worsened all scenarios. One illustrative finding is that the minimum level of common
393 restrictions to avoid resurgence in the reference setup has doubled from a low 0.29 (Alpha) to medium
394 0.62 (Delta).

395 Changing key parameters such as vaccine effectiveness, (re-)vaccination rate, or waning immunity
396 rate to realistic levels found in studies or certain countries shows the expected effect these changes would
397 have on infection dynamics. We quantified these effects by evaluating the times to overcriticality, asymp-
398 totic instantaneous reproduction number R^* , minimum necessary common restriction level that avoids
399 resurgence in the long term, and numbers of cases per million in the endemic state, for the relevant range
400 of possible restrictions for the VP holders and the rest of the population. As expected, the model shows
401 that there is a larger selection of admissible restrictions' combinations under high vaccine effectiveness,
402 low share of never vaccinated, a higher (re-)vaccination rate, slowly waning immunity, and proportional
403 social mixing. For the Delta variant, however, and even for optimistic of these parameter setups, the
404 room for manoeuvre in terms of lowering the restrictions is very small. Moreover, not all of these pa-
405 rameters are amenable to policy action. In a nutshell, our results consistently suggest that with the Delta
406 variant and with the way the vaccination program and introduction of VPs is currently implemented,
407 unfavourable developments of the epidemic are likely, and to counteract these developments and to max-
408 imize possible freedoms for their citizens, decision makers should exploit all possibilities to enhance the
409 development of effective vaccines, increase vaccination speed and the number of vaccinated.

410 It is noteworthy that VP holders are less likely to be tested, as they are assumed to be protected and
411 they may exhibit milder symptoms. Therefore, their potential infection is more likely to remain unde-
412 tected, resulting in an effect similar to that of lowering restrictions. To prevent undesirable outcomes, the
413 testing and quarantine criteria should be applicable also to the VP holders. Testing should aim at detec-
414 tion of vaccinated people that have lost, or have never gained, immunity. Finally, temporary VPs could
415 be considered, with their prolongation conditioned on high antibody level or recent (re-)vaccination.

416 The utilisation of tools such as the VAP-SIRS model, along with different tools available to policy-
417 makers should be explored in the context of monitoring the implementation of VPs, including the EU
418 DCC measures, to ensure optimisation of key parameters. In this manner, evidence-informed policy-
419 making would be safeguarded as would the best possible outcomes in terms of effectively combatting
420 the current pandemic.

421 **Methods**

422 **Mathematical model**

423 We introduce a modified susceptible-infectious-recovered-susceptible (SIRS) model [39] (Fig. 1a). The
424 population is divided into two subpopulations: those who are not vaccinated (S, I, R) and those who
425 got vaccinated at least once (S_V, I_V, R_V, V). We assume that the group of non-vaccinated susceptible
426 individuals S (and, similarly, infected I and recovered R) is divided into two subgroups: S_N and S_D .
427 The S_N compartment contains such susceptible who will eventually be vaccinated, while those in S_D
428 will not.

429 The S_N population is vaccinated with rate v and effectiveness a . Consequently, the individuals from
430 the S_N group populate the vaccinated group V with rate av . The individuals in V are considered immune,
431 and we assume that immunization prevents them both from getting infected and infecting others. The
432 S_V compartment is composed of S_1 and S_2 (and, similarly, vaccinated infected I_V consists of I_1 and
433 I_2). Due to vaccine ineffectiveness, people in S_1 are perceived as immunized, but in fact are susceptible.
434 S_1 is populated from S_N with rate $(1 - a)v$. The vaccinated from the V group move to the S_2 group of
435 susceptibles with immunity waning rate ω . The individuals from the S_1 group move to S_2 with the same
436 rate ω . The S_2 group is the group of vaccinated, but no longer immune, and thus, susceptible individuals.
437 In contrast to S_1 , we consider that the S_2 group is subject to revaccination. Consequently, a fraction of
438 size a of the population from S_2 populates V with rate av_r and a fraction of size $(1 - a)$ populates S_1
439 with rate $(1 - a)v_r$. Across the manuscript, we assume $v_r = v$, but the model is general and different
440 values can be considered. Individuals from S_1 move to S_2 with rate ω to ensure that the ineffectively
441 vaccinated are revaccinated with the same speed as the ones for which the vaccine was effective.

442 Some of the susceptibles in S_1 (or, similarly, S_2) may not get revaccinated fast enough and may
443 become infected and populate I_1 (or, I_2). Then, as in the classical SIRS model, the I_1 (or I_2) population
444 recovers and populates group R_V with rate γ . We consider that the recovered in R_V may also lose
445 the immunity, and become susceptible again and move to S_2 with rate κ . The remaining susceptible

446 subgroups (the S_N and S_D) may undergo the same classical dynamics, i.e., become infected, recover,
447 and either become susceptible again or, in case of the recovered in the R_N subgroup, become vaccinated
448 with rate v .

449 The following parameters are used to describe population dynamics in the model:

- f_v, f : restrictions level (for VP holders and others)
- β_0 : basic transmission rate
- β_v, β : transmission rate (for VP holders and others)
- γ : recovery rate
- κ : natural immunity waning rate
- a : vaccination effectiveness
- v : vaccination rate
- v_r : revaccination rate
- ω : vaccine-induced immunity waning rate
- d : fraction of population that will never get vaccinated

450 Finally, the following set of ordinary differential equations (ODEs) defines the dynamics

$$\begin{aligned}
 \frac{d}{dt}S_D &= -(\beta I + \beta I_V) S_D + \kappa R_D, \\
 \frac{d}{dt}S_N &= -(\beta I + \beta I_V) S_N - v S_N + \kappa R_N, \\
 \frac{d}{dt}S_1 &= v_r (1 - a) S_2 + v (1 - a) S_N - \omega S_1 - (\beta I + \beta_v I_V) S_1, \\
 \frac{d}{dt}S_2 &= -v_r S_2 + \omega V + \omega S_1 - (\beta I + \beta_v I_V) S_2 + \kappa R_V, \\
 \frac{d}{dt}V &= v a S_N + v_r a S_2 - \omega V + v_r R_V + v R_N, \\
 \frac{d}{dt}I_D &= (\beta I + \beta I_V) S_D - \gamma I_D, \\
 \frac{d}{dt}I_N &= (\beta I + \beta I_V) S_N - \gamma I_N, \\
 \frac{d}{dt}I_1 &= (\beta I + \beta_v I_V) S_1 - \gamma I_1, \\
 \frac{d}{dt}I_2 &= (\beta I + \beta_v I_V) S_2 - \gamma I_2, \\
 \frac{d}{dt}R_V &= \gamma I_V - \kappa R_V - v_r R_V, \\
 \frac{d}{dt}R_D &= \gamma I_D - \kappa R_D, \\
 \frac{d}{dt}R_N &= \gamma I_N - \kappa R_N - v R_N,
 \end{aligned} \tag{1}$$

451 where also the following relations hold

$$\begin{aligned}
 S_V &= S_1 + S_2, \\
 I_V &= I_1 + I_2, \\
 S &= S_D + S_N, \\
 I &= I_D + I_N, \\
 R &= R_N + R_D,
 \end{aligned}$$

452 with the constraint $S, S_V, I, I_V, R, R_V \geq 0$. Finally, to consider the subpopulation dynamics in terms of
 453 fractions of the entire subpopulation, we set

$$S + S_V + I + I_V + R + R_V + V = 1 \tag{2}$$

and denote d to be the fraction of the never-vaccinated population

$$d = S_D + I_D + R_D.$$

454 **Modeling restrictions**

455 We assume that the VP holders consist of the following subpopulations of vaccinated at least once:
456 V, S_V, I_V, R_V . Recall that the net effect of all non-pharmaceutical interventions is modeled using pa-
457 rameters f_v and f , called restrictions throughout the text. The parameter f_v amounts to the level of
458 restriction of contacts, and thus the ability to infect, within the group of VP holders. The parameter f
459 satisfies $f \geq f_v$ and corresponds to restriction of contacts within the rest of the population, as well as
460 between the VP holders and the rest of the population.

461 The restriction level f_v for the VP holders is introduced in the model as a modulator of the trans-
462 mission rate β_v . Specifically, we assume that $\beta_v = \beta_0(1 - f_v)$, where β_0 is the transmission rate of the
463 SARS-CoV-2 virus without restrictions. We assume f_v ranges from 0 to 1, where $f_v = 0$ corresponds
464 to no restrictions enforced on the VP holders, and $f_v = 1$ corresponding to full restrictions. Given that
465 for $f_v = 0$ the reproduction number $R_{\max} = \beta_0/\gamma$, and that the recovery rate $\gamma = 1/6$, we obtain the
466 no-restriction transmission rate $\beta_0 = R_{\max}/6$. Thus, for the Delta variant, with $R_{\max} = 6$, $\beta_0 = 1$

467 Similarly, the transmission rate parameter $\beta = \beta_0(1 - f)$ describes the transmission rate within the
468 rest of the population and between VP holders and the rest, given the restrictions f .

469 **Proportional versus preferential types of social mixing**

470 The above described model equations are based on the assumption that the social mixing between social
471 groups in the population is proportional to the group sizes (the mass action principle). Instead, prefer-
472 ential mixing can be assumed, where the VP holders are more likely to contact other VP holders, since
473 they have lower restrictions [53]. This preferential bias is proportional to the difference between the
474 restrictions f and f_v . To incorporate the preferential mixing effect in the ODE model (Equation 1) we
475 rescale the interaction terms according to the following rules:

$$\begin{aligned} S_V I_V &\rightarrow \frac{\beta_v}{\beta(S + I + R) + \beta_v(1 - (S + I + R))} S_V I_V \\ S I_V &\rightarrow \frac{\beta}{\beta(S + I + R) + \beta_v(1 - (S + I + R))} S I_V, \end{aligned}$$

476 where $S + I + R$ is the non-immune population.

477 **Model simulations**

478 For simulations, we solve the model numerically by means of joint Adams' and BDF methods, as im-
479 plemented in the R package deSolve, lsoda method of the ode function [54]. The method monitors data
480 in order to select between non-stiff (Adams') and stiff (BDF) methods. It uses the non-stiff method
481 initially [55].

482 To generate the data presented in Figure 1b, we use the reference setup of parameters for the Delta
483 variant: $\beta_0 = 1$, $f = 0.77$ (and thus $\beta = 0.23$), $f_v = 0.55$ (and thus $\beta_v = 0.45$), $\gamma = 1/6$, $\kappa = 1/500$,
484 $a = 0.79$, $v = v_r = 1/250$, $\omega = 1/500$, $d = 0.12$, with initial conditions $I = 10^{-6}$, $I_D = d \cdot I = 10^{-7}$;
485 $I_N = (1 - d) \cdot I = 0.9 \cdot 10^{-6}$, $R = 0$, $V = 0$. Given $I(t)$ resulting from the solution of the model's
486 ODE system, to present the final results as easier interpretable cases per million rather than fractions,
487 we re-scale the results by 1M. Additionally, we compute a proxy for the daily incidence number of new
488 cases from the following relation between $I(t)$ and $I^*(t)$:

$$\begin{aligned} I(t) &= \int_0^t e^{-\gamma(t-\tau)} I^*(\tau) d\tau \\ &= \int_{t-1}^t e^{-\gamma(t-\tau)} I^*(\tau) d\tau + e^{-\gamma} \int_0^{t-1} e^{-\gamma(t-1-\tau)} I^*(\tau) d\tau \\ &\simeq \frac{1}{\gamma} I^*(t) (1 - e^{-\gamma}) + e^{-\gamma} I(t-1). \end{aligned}$$

489 Thus, the $I^*(t)$ is computed as

$$I^*(t) \simeq \frac{\gamma}{1 - e^{-\gamma}} (I(t) - e^{-\gamma} I(t-1)).$$

490 We proceed similarly to obtain daily incidence numbers I_1^* , I_2^* and for the sum of all infected, and again
491 to make it interpretable in the figures we re-scale it by 1M.

492 **Stability analysis**

493 The vaccination dynamics can be solved explicitly in the absence of infections. Fixing $I = I_V = R =$
 494 $R_V = 0$, and assuming $v = v_r$, we obtain

$$\begin{aligned} S(t) &= d + (1 - d) e^{-vt}, \\ V(t) &= (1 - d) \frac{va}{va + \omega} \left(1 - e^{-(va+\omega)t} \right), \\ S_V(t) &= 1 - S - V. \end{aligned}$$

495 For convenience, where it is not needed, we drop the time argument.

Taking an adiabatic approach we linearize the infection dynamics for small I , I_V and R under the assumption of slowly varying S , S_V and V . In that case, the infection dynamics decouples from the vaccination dynamics and the Jacobian submatrix J_{sub} for the equations for I and I_V is given by:

$$J_{sub} = \begin{pmatrix} \beta S - \gamma & \beta S \\ \beta S_V & \beta_V S_V - \gamma \end{pmatrix}.$$

496 Given the Jacobian submatrix, we can approximate the dynamics in a small neighborhood of the $I =$
 497 $I_V = 0$ state as

$$\begin{pmatrix} \frac{d}{dt} I \\ \frac{d}{dt} I_V \end{pmatrix} = \begin{pmatrix} \beta S - \gamma & \beta S \\ \beta S_V & \beta_V S_V - \gamma \end{pmatrix} \cdot \begin{pmatrix} I \\ I_V \end{pmatrix}. \quad (3)$$

498 **The instantaneous reproduction number R^* and the instantaneous doubling time D**

499 Since the largest and the second largest eigenvalues λ_{max} and λ_2 of J_{sub} are both real, the solution to
 500 Equation 3 providing the dynamics of infection numbers of the vaccinated and the rest of the population
 501 in time can be written in the following form

$$\begin{pmatrix} I(t) \\ I_V(t) \end{pmatrix} = c_1 w_1 e^{\lambda_{max} t} + c_2 w_2 e^{\lambda_2 t} = e^{\lambda_{max} t} (c_1 w_1 + c_2 w_2 e^{(\lambda_2 - \lambda_{max}) t}), \quad (4)$$

502 where w_1 and w_2 are the respective eigenvectors, and c_1 and c_2 are constants depending on the initial
 503 conditions.

504 Since we have $\lambda_2 - \lambda_{\max} \leq 0$, we can approximate the time evolution of infection numbers by

$$\begin{pmatrix} I(t) \\ I_V(t) \end{pmatrix} \approx c_1 w_1 e^{\lambda_{\max} t}. \quad (5)$$

505 The largest eigenvalue of J_{sub} is given by

$$\lambda_{\max} = \frac{1}{2} S\beta - \gamma + \frac{1}{2} S_V \beta_v + \frac{1}{2} \sqrt{S^2 \beta^2 + S_V^2 \beta_v^2 - 2SS_V \beta \beta_v + 4SS_V \beta^2}, \quad (6)$$

506 whereby it is convenient to express λ_{\max} as a function of $R_1 = \frac{\beta}{\gamma}$ and $R_2 = \frac{\beta_v}{\gamma}$. We then obtain

$$\lambda_{\max} = \gamma \left(\frac{1}{2} (R_1 S + R_2 S_V) + \frac{1}{2} \sqrt{(R_1 S - R_2 S_V)^2 + 4SS_V R_1^2 - 1} \right). \quad (7)$$

507 Given the population fractions $S(t)$ and $S_V(t)$ at a given time instant t , the linearized dynamics of
 508 infections given by Equation 3 has a corresponding two-type Galton-Watson branching process, which
 509 is a microscopic description of the dynamics. The two types of the process correspond to the I and I_V
 510 groups. The type I individuals generate $Pois(R_1 S)$ offsprings of type I and $Pois(R_1 S_V)$ offsprings
 511 of type I_V . The type I_V individuals generate $Pois(R_1 S)$ offsprings of type I and $Pois(R_2 S_V)$ off-
 512 springs of type I_V . The linearized dynamics (3) can then be understood as a mean field limit of the
 513 microdynamics described by such a branching process. Moreover, the spectral norm

$$R^* = \frac{1}{2} (R_1 S + R_2 S_V) + \frac{1}{2} \sqrt{4R_1^2 S S_V + (R_1 S - R_2 S_V)^2} \quad (8)$$

of the transition matrix

$$\begin{pmatrix} R_1 S & R_1 S_V \\ R_1 S & R_2 S_V \end{pmatrix}$$

514 of the branching process can be interpreted as the reproduction number of the branching process, since
 515 the expected number of infected in generation n grows like $const \cdot (R^*)^n$ [56]. We refer to R^* as the
 516 instantaneous reproduction number. The term instantaneous comes from the fact that we are considering
 517 the linearized adiabatic dynamics in a small neighborhood of the $I = I_V = 0$ (ref Eq. 3).

The above discrete branching process can be extended to a continuous time branching process by assuming a probability distribution on the generation time, denoted $\varphi(\gamma)$. The growth of the continuous time branching process $const \cdot e^{\alpha t}$ is characterized by its Malthusian growth parameter, denoted α . The relation between the instantaneous reproduction number R^* , the distribution $\varphi(\tau)$ and the Malthusian

parameter α for such a branching process is given by

$$R^* \cdot \mathcal{L}_\varphi(\alpha) = 1$$

518 where $\mathcal{L}_\varphi(\alpha)$ is the Laplace transform $\int_0^\infty e^{-\alpha\tau} \varphi(\tau) d\tau$ of the distribution φ [56]. Since the setting
519 of ODE model (1) implies exponential distribution of the generation time, i.e, $\varphi(\gamma) = \text{Exp}(\gamma)$, the
520 following relation holds: $\alpha = \gamma(R^* - 1)$.

521 By Equation 5, the Malthusian parameter α for our dynamics is given by the largest eigenvalue
522 λ_{\max} . Hence we obtain the relation between the instantaneous reproduction R^* and the λ_{\max} as $\lambda_{\max} =$
523 $\gamma(R^* - 1)$. Note that since both S and S_V are functions of time, so are λ_{\max} and R^* .

524 It is noteworthy that in the above equations, all R_1 , R_2 , R_1S and R_2S_V , and R^* should be seen
525 as reproduction numbers, but of a different nature [57]. R_1 and R_2 are reproduction numbers taking
526 into account the restrictions f and f_v , respectively. The R_1S and R_2S_V are also group specific, but in
527 addition incorporate the respective group sizes. Finally, R^* combines all these factors together.

528 Having this and Equation 5, we define the instantaneous doubling time at time, denoted $t D(t)$, as
529 the solution D of $e^{\gamma(R^*(t)-1) \cdot D} = 2$. Such obtained doubling times are featured in Supplementary Figure
530 S1.

531 **The times of transitions between subcritical and overcritical epidemics**

The analysis of the linearized dynamics around $I = I_V = 0$ allows us to determine transitions between subcritical and overcritical epidemics. Such transitions occur at the time instants t at which $\lambda_{\max}(t) = 0$, or, equivalently, at $R^*(t) = 1$. We thus find that for given values of $S(t)$ and $S_V(t)$ the critical times t for transitions between subcritical and overcritical epidemics are the roots of the equation

$$\lambda_{\max}(t) = 0.$$

532 The obtained critical threshold times are plotted in the lower triangles of the panels in Figures 2 and 3 in
533 the main text. In the case of proportional mixing the above equation is equivalent to:

$$(R_1S(t) - 1)(R_2S_V(t) - 1) = R_1^2S(t)S_V(t).$$

534 **Asymptotic structure of the population**

535 The asymptotic structure of the population in terms of the sizes of the subpopulations V , S_V and S_D can
536 be easily obtained by setting $I = I_V = R = R_V = 0$ and computing the stable stationary solution for
537 V^{as} , S^{as} and S_V^{as} of our ODE system 1:

$$\begin{aligned}S^{\text{as}} &= d \\S_V^{\text{as}} &= (1 - d)(1 - \eta) \\V^{\text{as}} &= (1 - d)\eta \\S^{\text{as}} + S_V^{\text{as}} &= 1 - V^{\text{as}},\end{aligned}$$

where

$$\eta = \frac{a}{1 + \omega/v_r}$$

538 can be seen as the actual immunization rate in the population, and is expressed as a function of vaccine
539 effectiveness a and the ratio of the immunity waning rate ω and the revaccination rate v_r . The obtained
540 values correspond to the structure in the limit $t \rightarrow \infty$ and represent the structure to which the population
541 converges in the long term.

542 Having this, we obtain the asymptotic instantaneous reproduction number R^* by inserting the asymp-
543 totic values S^{as} and S_V^{as} into Equation 8. These values are plotted in the upper triangles in the panels of
544 Figures 2 and 3 in the main text.

Finally, we solve for such minimum common restrictions $f = f_v = f_{\text{min}}$, which will result in
instantaneous reproduction number $R^* = 1$ for the different vaccine effectiveness and vaccination rate
setups. Hence f_{min} is found from $R_{\text{max}}(1 - f_{\text{min}}) = \frac{1}{1-V}$ as

$$f_{\text{min}} = \max\left(0, 1 - \frac{1}{R_{\text{max}}(1 - V^{\text{as}})}\right).$$

545 Endemic state

546 The endemic state of the VAP-SIRS model is obtained by setting the derivatives of the ODE system 1 to
 547 0. A straightforward computation reduces the endemic system of equations to the following:

$$0 = (\beta I + \delta^+ I_V) \left(d - I - \frac{\gamma}{\kappa} I \right) - \gamma I \quad (9)$$

$$0 = \frac{v_1^* \alpha (v_2 + \beta I + \delta^* I_V) \cdot \gamma I_V}{(\beta I + \delta^* I_V + v_2 + v_1^* (1 - \alpha))} - v_2 \left(1 - d - I_V - \frac{\gamma}{\kappa + v_1^*} I_V \right) (\beta I + \delta^* I_V) + v_2 \gamma I_V + v_1^* \frac{\gamma}{\kappa + v_1^*} I_V \cdot (\beta I + \delta^* I_V) \quad (10)$$

$$S = d - I \left(1 + \frac{\gamma}{\kappa} \right)$$

$$S_V = \frac{\gamma I_V}{\beta I + \delta^* I_V}$$

$$R = \frac{\gamma}{\kappa} I$$

$$R_V = \frac{\gamma}{\kappa + v_1} I_V$$

$$V = 1 - d - S - S_V - I - I_V - R - R_V,$$

548 where for the proportional mixing we have: $\delta^* = \delta$ and $\delta^+ = \beta$, and for the preferential mixing we set
 549 $\delta^* = \frac{\delta^2}{\beta d + \delta(1-d)}$ and $\delta^+ = \frac{\beta^2}{\beta d + \delta(1-d)}$. The roots of the Equations 9 and 10 are plotted in Figures 4 and 5.

550

551 **Data and materials availability** The VAP-SIRS model was implemented using R version 4.0.2 along
 552 with the shiny package to build an interactive web application that allows to simulate the model. The
 553 code of the model is available online in the GitHub repository: [https://github.com/storaged/](https://github.com/storaged/VAP-SIRS)
 554 [VAP-SIRS](https://github.com/storaged/VAP-SIRS), and the on-line tool is available <http://bioputer.mimuw.edu.pl:85/VAP-SIRS/>.
 555 The code to generate Figures 2-5 from the main text is available at [https://github.com/eMaerthin/](https://github.com/eMaerthin/VAP_SIRS_Analysis)
 556 [VAP_SIRS_Analysis](https://github.com/eMaerthin/VAP_SIRS_Analysis).

557 References

- 558 1. *International health regulations (2005)* Third edition (ed World Health Organization) (World Health
 559 Organization, Geneva, Switzerland, 2016).
- 560 2. Voo, T. C. *et al.* Immunity certification for COVID-19: ethical considerations. *Bulletin of the World*
 561 *Health Organization* **99**, 155–161. (2021) (Feb. 2021).

- 562 3. Brown, R. C. H., Kelly, D., Wilkinson, D. & Savulescu, J. The scientific and ethical feasibility of
563 immunity passports. en. *The Lancet Infectious Diseases* **21**, e58–e63. (2021) (Mar. 2021).
- 564 4. European Commission, Directorate-General for Justice and Consumers. *Proposal for a REGU-*
565 *LATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on a framework for the*
566 *issuance, verification and acceptance of interoperable certificates on vaccination, testing and re-*
567 *covery to facilitate free movement during the COVID-19 pandemic (Digital Green Certificate, Doc-*
568 *ument 52021PC0130)* [https://eur-lex.europa.eu/legal-content/EN/TXT/](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52021PC0130)
569 [?uri=CELEX:52021PC0130](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52021PC0130) (2021).
- 570 5. European Commission, Directorate-General for Justice and Consumers. *Regulation (EU) 2021/954*
571 *of the European Parliament and of the Council of 14 June 2021 on a framework for the issuance,*
572 *verification and acceptance of interoperable COVID-19 vaccination, test and recovery certificates*
573 *(EU Digital COVID Certificate) with regard to third-country nationals legally staying or residing*
574 *in the territories of Member States during the COVID-19 pandemic (Text with EEA relevance),*
575 *Document 32021R0954* [https://eur-lex.europa.eu/legal-content/en/TXT/](https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX:32021R0954)
576 [?uri=CELEX:32021R0954](https://eur-lex.europa.eu/legal-content/en/TXT/?uri=CELEX:32021R0954) (2021).
- 577 6. Centers for Disease Control and Prevention. *SARS-CoV-2 Variant Classifications and Definitions*
578 *tech. rep. (CDC).* [https://www.cdc.gov/coronavirus/2019-ncov/variants/](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html)
579 [variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html) (2021).
- 580 7. Burki, T. K. Lifting of COVID-19 restrictions in the UK and the Delta variant. *The Lancet Res-*
581 *piratory Medicine.* [https://doi.org/10.1016/s2213-2600\(21\)00328-3](https://doi.org/10.1016/s2213-2600(21)00328-3) (July
582 2021).
- 583 8. Callaway, E. Delta coronavirus variant: scientists brace for impact. *Nature* **595**, 17–18. <https://doi.org/10.1038/d41586-021-01696-3> (June 2021).
- 585 9. European Centre for Disease Control and Prevention. *Implications for the EU/EEA on the spread of*
586 *the SARS-CoV-2 Delta (B.1.617.2) variant of concern* tech. rep. (ECDC). [https://www.ecdc.](https://www.ecdc.europa.eu/sites/default/files/documents/Implications-for-the-EU-EEA-on-the-spread-of-SARS-CoV-2-Delta-VOC-23-June-2021_1.pdf)
587 [europa.eu/sites/default/files/documents/Implications-for-the-EU-](https://www.ecdc.europa.eu/sites/default/files/documents/Implications-for-the-EU-EEA-on-the-spread-of-SARS-CoV-2-Delta-VOC-23-June-2021_1.pdf)
588 [EEA-on-the-spread-of-SARS-CoV-2-Delta-VOC-23-June-2021_1.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/Implications-for-the-EU-EEA-on-the-spread-of-SARS-CoV-2-Delta-VOC-23-June-2021_1.pdf)
589 (2021).
- 590 10. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in Eng-
591 land. <https://doi.org/10.1101/2020.12.24.20248822> (Dec. 2020).

- 592 11. Allen, H. *et al.* Increased household transmission of COVID-19 cases associated with SARS-CoV-2
593 Variant of Concern B.1.617.2: a national case- control study (pre-print) tech. rep. (). [https://khub.net/documents/135939561/405676950/Increased+Household+](https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa)
594 [Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-](https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa)
595 [ecb0-da31-77b3-b1a8ef7be9aa](https://khub.net/documents/135939561/405676950/Increased+Household+Transmission+of+COVID-19+Cases+-+national+case+study.pdf/7f7764fb-ecb0-da31-77b3-b1a8ef7be9aa) (2021).
596
- 597 12. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on
598 immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four
599 randomised trials. en. *The Lancet* **397**, 881–891. (2021) (Mar. 2021).
- 600 13. Thompson, M. G. *et al.* Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-
601 1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel,
602 First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December
603 2020–March 2021. *MMWR. Morbidity and Mortality Weekly Report* **70**, 495–500. (2021) (Apr.
604 2021).
- 605 14. Bian, L. *et al.* Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. en.
606 *Expert Review of Vaccines*, 1–9. (2021) (Apr. 2021).
- 607 15. Chia, W. N. *et al.* Dynamics of SARS-CoV-2 neutralising antibody responses and duration of
608 immunity: a longitudinal study. *The Lancet Microbe*. [https://doi.org/10.1016/s2666-](https://doi.org/10.1016/s2666-5247(21)00025-2)
609 [5247\(21\)00025-2](https://doi.org/10.1016/s2666-5247(21)00025-2) (Mar. 2021).
- 610 16. Iyer, A. S. *et al.* Persistence and decay of human antibody responses to the receptor binding domain
611 of SARS-CoV-2 spike protein in COVID-19 patients. en. *Science Immunology* **5**, eabe0367. (2021)
612 (Oct. 2020).
- 613 17. Hall, V. J. *et al.* SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative
614 health-care workers in England: a large, multicentre, prospective cohort study (SIREN). en. *The*
615 *Lancet* **397**, 1459–1469. (2021) (Apr. 2021).
- 616 18. Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K. & Ethelberg, S. Assessment of protec-
617 tion against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in
618 2020: a population-level observational study. en. *The Lancet* **397**, 1204–1212. (2021) (Mar. 2021).
- 619 19. Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. <https://doi.org/10.1101/2021.05.22.21257658> (May 2021).
620

- 621 20. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland:
622 demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet* **397**, 2461–2462.
623 [https://doi.org/10.1016/s0140-6736\(21\)01358-1](https://doi.org/10.1016/s0140-6736(21)01358-1) (June 2021).
- 624 21. Nasreen, S. *et al.* Effectiveness of COVID-19 vaccines against variants of concern, Canada. <https://doi.org/10.1101/2021.06.28.21259420> (July 2021).
- 626 22. Israel Ministry of Health. *Decline in Vaccine Effectiveness Against Infection and Symptomatic Ill-*
627 *ness* tech. rep. (IMoH). [https://www.gov.il/en/departments/news/05072021-](https://www.gov.il/en/departments/news/05072021-03)
628 [03](https://www.gov.il/en/departments/news/05072021-03) (2021).
- 629 23. Iftekhar, E. N. *et al.* *A look into the future of the COVID-19 pandemic in Europe: an expert consul-*
630 *tation* 2021.
- 631 24. Phillips, S. & Williams, M. A. Confronting Our Next National Health Disaster — Long-Haul
632 Covid. *New England Journal of Medicine*. <https://doi.org/10.1056/nejmp2109285>
633 (June 2021).
- 634 25. Augustin, M. *et al.* Post-COVID syndrome in non-hospitalised patients with COVID-19: a lon-
635 gitudinal prospective cohort study. *The Lancet Regional Health - Europe* **6**, 100122. <https://doi.org/10.1016/j.lanepe.2021.100122> (July 2021).
- 637 26. Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews*
638 *Microbiology* **19**, 409–424. <https://doi.org/10.1038/s41579-021-00573-0> (June
639 2021).
- 640 27. Sadarangani, M. *et al.* Importance of COVID-19 vaccine efficacy in older age groups. en. *Vaccine*
641 **39**, 2020–2023. (2021) (Apr. 2021).
- 642 28. Prieto Curiel, R. & González Ramírez, H. Vaccination strategies against COVID-19 and the diffu-
643 sion of anti-vaccination views. en. *Scientific Reports* **11**, 6626. (2021) (Dec. 2021).
- 644 29. Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L. & Keeling, M. J. Vaccination and non-pharmaceutical
645 interventions for COVID-19: a mathematical modelling study. en. *The Lancet Infectious Diseases*,
646 S1473309921001432. (2021) (Mar. 2021).
- 647 30. Lee, B. Y. *et al.* Vaccination Deep Into a Pandemic Wave. en. *American Journal of Preventive*
648 *Medicine* **39**, e21–e29. (2021) (Nov. 2010).

- 649 31. Jentsch, P. C., Anand, M. & Bauch, C. T. Prioritising COVID-19 vaccination in changing social and
650 epidemiological landscapes: a mathematical modelling study. en. *The Lancet Infectious Diseases*,
651 S1473309921000578. (2021) (Mar. 2021).
- 652 32. Bubar, K. M. *et al.* Model-informed COVID-19 vaccine prioritization strategies by age and serosta-
653 tus. en. *Science* **371**, 916–921. (2021) (Feb. 2021).
- 654 33. Bauer, S. *et al.* Relaxing restrictions at the pace of vaccination increases freedom and guards against
655 further COVID-19 waves in Europe. *arXiv:2103.06228 [q-bio]*. arXiv: 2103.06228. [http://](http://arxiv.org/abs/2103.06228)
656 arxiv.org/abs/2103.06228 (2021) (Mar. 2021).
- 657 34. Giordano, G. *et al.* Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for
658 non-pharmaceutical interventions in Italy. en. *Nature Medicine*. (2021) (Apr. 2021).
- 659 35. Moghadas, S. M. *et al.* Evaluation of COVID-19 vaccination strategies with a delayed second dose.
660 en. *PLOS Biology* **19** (ed Read, A. F.) e3001211. (2021) (Apr. 2021).
- 661 36. Makhoul, M. *et al.* Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling
662 Analyses. en. *Vaccines* **8**, 668. (2021) (Nov. 2020).
- 663 37. Viana, J. *et al.* Controlling the pandemic during the SARS-CoV-2 vaccination rollout. *Nature Com-*
664 *munications* **12**. <https://doi.org/10.1038/s41467-021-23938-8> (June 2021).
- 665 38. Sandmann, F. G. *et al.* The potential health and economic value of SARS-CoV-2 vaccination along-
666 side physical distancing in the UK: a transmission model-based future scenario analysis and eco-
667 nomic evaluation. *The Lancet Infectious Diseases* **21**, 962–974. [https://doi.org/10.](https://doi.org/10.1016/s1473-3099(21)00079-7)
668 [1016/s1473-3099\(21\)00079-7](https://doi.org/10.1016/s1473-3099(21)00079-7) (July 2021).
- 669 39. Keeling, M. J. & Rohani, P. *Modeling Infectious Diseases in Humans and Animals* (2021) (Prince-
670 ton University Press, Sept. 2011).
- 671 40. Ritchie, H. *et al.* *Coronavirus (COVID-19) Vaccinations* [https://ourworldindata.org/](https://ourworldindata.org/covid-vaccinations)
672 [covid-vaccinations](https://ourworldindata.org/covid-vaccinations) (2021).
- 673 41. European Centre for Disease Prevention and Control (ECDC). *COVID-19 Vaccine Tracker* [https:](https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html)
674 [//vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-](https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html)
675 [tracker.html](https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html) (2021).
- 676 42. Letizia, A. G. *et al.* SARS-CoV-2 seropositivity and subsequent infection risk in healthy young
677 adults: a prospective cohort study. en. *The Lancet Respiratory Medicine*, S2213260021001582.
678 (2021) (Apr. 2021).

- 679 43. Rockstroh, A. *et al.* Correlation of humoral immune responses to different SARS-CoV-2 antigens
680 with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort. en.
681 *Emerging Microbes & Infections* **10**, 774–781. (2021) (Jan. 2021).
- 682 44. Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
683 en. *Science* **370**, 1227–1230. (2021) (Dec. 2020).
- 684 45. Tarke, A. *et al.* Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactiv-
685 ity in COVID-19 exposed donors and vaccinees. *bioRxiv*. [https://www.biorxiv.org/
686 content/early/2021/03/01/2021.02.27.433180](https://www.biorxiv.org/content/early/2021/03/01/2021.02.27.433180) (2021).
- 687 46. Chia, W. N. *et al.* Dynamics of SARS-CoV-2 neutralising antibody responses and duration of
688 immunity: a longitudinal study. *The Lancet Microbe*. [https://doi.org/10.1016/s2666-
689 5247\(21\)00025-2](https://doi.org/10.1016/s2666-5247(21)00025-2) (Mar. 2021).
- 690 47. Zuo, J. *et al.* Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following
691 primary infection. *Nature Immunology*. [https://doi.org/10.1038/s41590-021-
692 00902-8](https://doi.org/10.1038/s41590-021-00902-8) (Mar. 2021).
- 693 48. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in Eng-
694 land. en. *Science* **372**, eabg3055. (2021) (Apr. 2021).
- 695 49. The COVID-19 Genomics UK (COG-UK) consortium *et al.* Assessing transmissibility of SARS-
696 CoV-2 lineage B.1.1.7 in England. en. *Nature*. (2021) (Mar. 2021).
- 697 50. Dagpunar, J. Interim estimates of increased transmissibility, growth rate, and reproduction number
698 of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. [https://doi.org/10.
699 1101/2021.06.03.21258293](https://doi.org/10.1101/2021.06.03.21258293) (June 2021).
- 700 51. Campbell, F. *et al.* Increased transmissibility and global spread of SARS-CoV-2 variants of concern
701 as at June 2021. *Eurosurveillance* **26**. [https://doi.org/10.2807/1560-7917.es.
702 2021.26.24.2100509](https://doi.org/10.2807/1560-7917.es.2021.26.24.2100509) (June 2021).
- 703 52. Priesemann, V. *et al.* Calling for pan-European commitment for rapid and sustained reduction in
704 SARS-CoV-2 infections. *Lancet* **397**, 92–93 (Jan. 2021).
- 705 53. Marschner, I. C. The effect of preferential mixing on the growth of an epidemic. *Mathematical*
706 *Biosciences* **109**, 39–67. [https://doi.org/10.1016/0025-5564\(92\)90051-w](https://doi.org/10.1016/0025-5564(92)90051-w) (Apr.
707 1992).

- 708 54. Soetaert, K., Petzoldt, T. & Setzer, R. W. Solving Differential Equations in R: PackagedeSolve.
709 *Journal of Statistical Software* **33**. <https://doi.org/10.18637/jss.v033.i09> (2010).
- 710 55. Hindmarsh, A. C. & Petzold, L. R. Algorithms and software for ordinary differential equations and
711 differential- algebraic equations, Part II: Higher-order methods and software packages. *Computers*
712 *in Physics* **9**, 148. <https://doi.org/10.1063/1.168540> (1995).
- 713 56. Athreya, K. B. & Ney, P. E. *Branching Processes* German. OCLC: 863789203. (2021) (Springer,
714 Berlin, Heidelberg, 1972).
- 715 57. Van den Driessche, P. Reproduction numbers of infectious disease models. en. *Infectious Disease*
716 *Modelling* **2**, 288–303. (2021) (Aug. 2017).

717 **Acknowledgments**

718 SC acknowledges support by University of Malta. EP acknowledges support by the University of Crete.
719 TC has received funding from the European Union’s Horizon 2020 research and innovation programme
720 under grant agreement No 101016233 (PERISCOPE). GG acknowledges support by the University of
721 Trento within the COVID-19 Strategic Project MOSES (Models for Reasoning about the Spreading of
722 Diseases). MP was supported by the Slovenian Research Agency (Grant Nos. P1-0403 and J1-2457). ES
723 acknowledges funding by the Polish National Science Centre OPUS grant no 2019/33/B/NZ2/00956.

724 **Authors contributions** AG, KG, TK, and ES conceived the VAP-SIRS model - with input and feed-
725 back on the model and results from TC, GG, MP, EP and MR. TK performed the stability analysis. KG
726 implemented model simulations and the Shiny application for visualizations. MB implemented the sta-
727 bility analysis. SC, TC, EP, and MR performed literature search. ES supervised the study. All authors
728 wrote and provided critical feedback to the manuscript.

729 **Competing interests** Other projects in the research lab of ES are co-funded by Merck Healthcare
730 KGaA.